,88,89,90 Our epigenome-editing approach for PD is based on a novel and engineered LV carrying CRISPR-dCas9 fused with the catalytic domain of the de novo DNMT3A enzyme.87 This evidence concerns the gene DNMT3A and Parkinson disease.